Researchers at the University of Texas MD Anderson Cancer Center published two studies this week on a new approach that could improve treatment for patients with pancreatic cancer. The preclinical studies showed that combining immunotherapy with a KRAS inhibitor can lead to long-lasting tumor elimination.
Oncology has long been borrowing lessons from immunology. It may now be time to pay it back. Pandion Therapeutics is tapping into some immune evasion tools observed in cancer to better treat autoimmune and inflammatory disorders.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Biopharma vet Deborah Dunsire has joined Waltham, Massachusetts-based XTuit Pharmaceuticals, a startup targeting the microenvironments that protect and drive certain cancers and fibrotic diseases.
Polaris Partners-backed XTuit Pharmaceuticals, a cancer-centric biotech that targets therapeutics in the tumor microenvironment, just raised $4 million from three investors – and, according to a regulatory filing, is planning to bring in $6 more. The company was founded in 2011 by Harvard professor Rakesh Jain, MIT chemical engineering professor Bob Langer and Polaris partner Alan […]